Allergan pulled up by FDA

Article

The FDA has sent Allergan a warning letter relating to misleading information printed in a professional journal advertisement for its ophthalmic solution, Acular LS.

The FDA has sent Allergan a warning letter relating to misleading information printed in a professional journal advertisement for its ophthalmic solution, Acular LS.

The FDA remonstrated Allergan for printing information that broadens the product's indication, presents unsubstantiated superiority claims and omits important risk information for Acular LS.

Acular LS, according to the FDA approved product labelling, is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.